VVP
UBX

Venture Visionary Partners’s Unity Biotechnology UBX Stock Holding History

Venture Visionary Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-62
Closed -$347 – 1472
2022
Q2 		$347 Buy
+62
New +$517 ﹤0.01% 1667

Other funds holding UBX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
ACM
Altium Capital Management New York $42M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Venture Visionary Partners's UBX Position: Q3 2022 in Review

Venture Visionary Partners sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 62 shares — an estimated $347 sold.

Venture Visionary Partners first reported a position in UBX in Q2 2022 and held it in 1 quarter. The position peaked at $347 in Q2 2022. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

  • Venture Visionary Partners reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 62 Unity Biotechnology shares in Q3 2022, an estimated $347.
  • Venture Visionary Partners first reported a position in Unity Biotechnology in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Unity Biotechnology position peaked at $347 in Q2 2022.
  • 72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.